Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Clinical trial NCT05296603 · UNKNOWN
Trial details
- NCT number
- NCT05296603
- Sponsor
- Hunan Province Tumor Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-03
- Primary completion
- 2024-10-30
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.